Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines. This expansion of their 2016 collaboration will ...

Moderna's ability to launch differentiated mRNA therapies beyond covid, ranging from prophylactic vaccines for other respiratory diseases to cancer treatments, will be key to establishing a moat ...

Moderna is down ... like a readout from the cancer vaccine trials would come in H1'25, and the CMV phase 3 study might not read out until later in 2025 either. I rate MRNA a sell then, because ...

Ellison said that artificial intelligence could be used to develop personalized mRNA-based cancer vaccines and early tumor detection. In 2024, Moderna (NASDAQ:MRNA) partnered with OpenAI to deploy ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

4 and two other circulating strains, he said, Moderna’s vaccine “could be able to cover upwards of 70 or 80% of the norovirus outbreaks that might occur in a given year. And with our mRNA ...